Malignant Melanoma: Epidemiologic Aspects, Diagnostic and Therapeutic Approach

Overview

Journal Wien Med Wochenschr

Specialty General Medicine

Date 2013 May 30

PMID 23715934

Citations 4

Authors

Michael Tronnier

Kristina Semkova

Uwe Wollina

Georgi Tchernev

Affiliations

Soon will be listed here.

Abstract

In faired skinned population the incidence of melanoma is rapidly increasing. Beside environmental factors (UV-exposure) certainly other reasons for the observed "melanoma epidemic" have to be discussed. For diagnostic procedure classical histopathology is accompanied by immunohistochemistry and more recently molecular techniques. For therapy new modalities are available which-after many years of frustrating search for new drugs-are now able to prolong both disease/progression free and overall survival.

Citing Articles

The diagnostic value of modified systemic ınflammation score in predicting post-operative outcomes of cutaneous melanoma patients who underwent ısolated limb perfusion.

Morkavuk S, Culcu S, Esen E, Unal A World J Surg Oncol. 2021; 19(1):327.

PMID: 34781987 PMC: 8594072. DOI: 10.1186/s12957-021-02437-6.

The value of metastasectomy in stage IV cutaneous melanoma.

Wollina U, Brzezinski P Wien Med Wochenschr. 2018; 169(13-14):331-338.

PMID: 29511905 DOI: 10.1007/s10354-018-0630-6.

Subungual Nail Pigmentation and Malalignment of the Great Toe Nail in a Cancer Patient - A Diagnostic Challenge.

Wollina U, Tchernev G Open Access Maced J Med Sci. 2017; 5(4):467-469.

PMID: 28785334 PMC: 5535659. DOI: 10.3889/oamjms.2017.084.

Treating advanced melanoma: current insights and opportunities.

Tronnier M, Mitteldorf C Cancer Manag Res. 2014; 6:349-56.

PMID: 25228821 PMC: 4164110. DOI: 10.2147/CMAR.S49494.

References

Zalaudek I, Docimo G, Argenziano G . Using dermoscopic criteria and patient-related factors for the management of pigmented melanocytic nevi. Arch Dermatol. 2009; 145(7):816-26. PMC: 2856040. DOI: 10.1001/archdermatol.2009.115. View

Herman C . Emerging technologies for the detection of melanoma: achieving better outcomes. Clin Cosmet Investig Dermatol. 2012; 5:195-212. PMC: 3508547. DOI: 10.2147/CCID.S27902. View

Bauer J, Bastian B . Distinguishing melanocytic nevi from melanoma by DNA copy number changes: comparative genomic hybridization as a research and diagnostic tool. Dermatol Ther. 2006; 19(1):40-9. DOI: 10.1111/j.1529-8019.2005.00055.x. View

Gerami P, Scolyer R, Xu X, Elder D, Abraham R, Fullen D . Risk assessment for atypical spitzoid melanocytic neoplasms using FISH to identify chromosomal copy number aberrations. Am J Surg Pathol. 2013; 37(5):676-84. DOI: 10.1097/PAS.0b013e3182753de6. View

Powell A, Robson A, Russell-Jones R, Barlow R . Imiquimod and lentigo maligna: a search for prognostic features in a clinicopathological study with long-term follow-up. Br J Dermatol. 2009; 160(5):994-8. DOI: 10.1111/j.1365-2133.2009.09032.x. View

Garbe C, Peris K, Hauschild A, Saiag P, Middleton M, Spatz A . Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline--Update 2012. Eur J Cancer. 2012; 48(15):2375-90. DOI: 10.1016/j.ejca.2012.06.013. View

Pflugfelder A, Weide B, Eigentler T, Forschner A, Leiter U, Held L . Incisional biopsy and melanoma prognosis: Facts and controversies. Clin Dermatol. 2010; 28(3):316-8. DOI: 10.1016/j.clindermatol.2009.06.013. View

Whiteman D, Whiteman C, Green A . Childhood sun exposure as a risk factor for melanoma: a systematic review of epidemiologic studies. Cancer Causes Control. 2001; 12(1):69-82. DOI: 10.1023/a:1008980919928. View

Choudhury K, Volkmer B, Greinert R, Christophers E, Breitbart E . Effectiveness of skin cancer screening programmes. Br J Dermatol. 2012; 167 Suppl 2:94-8. DOI: 10.1111/j.1365-2133.2012.11091.x. View

10.

Erdmann F, Lortet-Tieulent J, Schuz J, Zeeb H, Greinert R, Breitbart E . International trends in the incidence of malignant melanoma 1953-2008--are recent generations at higher or lower risk?. Int J Cancer. 2012; 132(2):385-400. DOI: 10.1002/ijc.27616. View

11.

Cerroni L, Barnhill R, Elder D, Gottlieb G, Heenan P, Kutzner H . Melanocytic tumors of uncertain malignant potential: results of a tutorial held at the XXIX Symposium of the International Society of Dermatopathology in Graz, October 2008. Am J Surg Pathol. 2010; 34(3):314-26. DOI: 10.1097/PAS.0b013e3181cf7fa0. View

12.

Garbe C, Leiter U . Melanoma epidemiology and trends. Clin Dermatol. 2008; 27(1):3-9. DOI: 10.1016/j.clindermatol.2008.09.001. View

13.

Flaherty K, Infante J, Daud A, Gonzalez R, Kefford R, Sosman J . Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012; 367(18):1694-703. PMC: 3549295. DOI: 10.1056/NEJMoa1210093. View

14.

Erickson C, Driscoll M . Melanoma epidemic: Facts and controversies. Clin Dermatol. 2010; 28(3):281-6. DOI: 10.1016/j.clindermatol.2009.06.021. View

15.

Menzies A, Long G, Murali R . Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Des Devel Ther. 2012; 6:391-405. PMC: 3523565. DOI: 10.2147/DDDT.S38998. View

16.

Sosman J, Kim K, Schuchter L, Gonzalez R, Pavlick A, Weber J . Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012; 366(8):707-14. PMC: 3724515. DOI: 10.1056/NEJMoa1112302. View

17.

Daponte A, Signoriello S, Maiorino L, Massidda B, Simeone E, Grimaldi A . Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma. J Transl Med. 2013; 11:38. PMC: 3598549. DOI: 10.1186/1479-5876-11-38. View

18.

Katalinic A, Waldmann A, Weinstock M, Geller A, Eisemann N, Greinert R . Does skin cancer screening save lives?: an observational study comparing trends in melanoma mortality in regions with and without screening. Cancer. 2012; 118(21):5395-402. DOI: 10.1002/cncr.27566. View

19.

Beger J, Hansel G, Kronert C, Fuchs M, Tanner C, Schonlebe J . A 10-year analysis of primary cutaneous malignant melanoma with sentinel lymph node biopsy and long-term follow-up. Int J Dermatol. 2013; 52(2):220-30. DOI: 10.1111/j.1365-4632.2012.05706.x. View

20.

Eggermont A, Suciu S, Santinami M, Testori A, Kruit W, Marsden J . Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet. 2008; 372(9633):117-126. DOI: 10.1016/S0140-6736(08)61033-8. View